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doi:10.1016/j.jtcvs.2004.03.020396 The Journal of Thoracic and CardioObjective: We sought to predict lymph node metastasis and tumor invasiveness in
clinical T1 N0 M0 lung adenocarcinomas, and we measured fluorodeoxyglucose
uptake on positron emission tomography.
Methods: Fluorodeoxyglucose positron emission tomography was performed on 44
patients with adenocarcinomas of 1 to 3 cm in size clinically staged as T1 N0 M0
before major lung resection with lymph node dissection. Fluorodeoxyglucose up-
take was evaluated by using the contrast ratio between the tumor and contralateral
healthy lung tissue. Lymphatic and vascular invasion within tumors, pleural in-
volvement, and grade of histologic differentiation were examined.
Results: The pathologic tumor stage was T1 N0 M0 in 36 patients, and a more
advanced stage was found in 8 patients. Although all 22 adenocarcinomas with a
contrast ratio of less than 0.5 in fluorodeoxyglucose uptake were pathologic T1 N0
M0 tumors, 8 (36%) of 22 with a contrast ratio of 0.5 or greater were of a more
advanced stage than T1 N0 M0, with the difference being significant (P  .002).
Adenocarcinomas with a contrast ratio of less than 0.5 showed less lymphatic and
vascular invasion and less pleural involvement than those with a contrast ratio of 0.5
or greater (P  .006, P  .004, and P  .02, respectively). The grade of histologic
differentiation was well differentiated in 19 of 22 adenocarcinomas with a contrast
ratio of less than 0.5 (86%), which was a greater frequency than the 4 (18%) of 22
adenocarcinomas with a contrast ratio of 0.5 or greater (P  .001).
Conclusion: Clinical T1 N0 M0 lung adenocarcinomas with a contrast ratio of less
than 0.5 usually did not have lymph node metastasis, had less tumor involvement of
vessels or pleura, and were more frequently well differentiated than those with a contrast
ratio of 0.5 or greater. Limited lung resection could be indicated, lymph node dissection
or mediastinoscopy could be reduced, or both in this type of adenocarcinoma.
vascular Surgery ● September 2004
Nomori et al General Thoracic Surgery
G
TSRecent advances in low-dose helical com-puted tomography (CT) and video-assistedthoracoscopic surgery have enabled the di-agnosis of lung cancers while still small insize.1-6 Although limited resection proce-dures, such as lung wedge resection or
segmentectomy, can cure some clinical T1 N0 M0 non–
small cell lung cancers (NSCLCs),7,8 lymph node metasta-
ses are still found in approximately 20% of clinical T1 N0
M0 lung adenocarcinomas.9-11 Even for patients with patho-
logic T1 N0 M0 NSCLCs, tumor involvement of intratu-
moral vessels or the pleura can also cause local recurrence
after limited resection because of the spread of tumor cells
into lymphatic vessels outside the primary tumor. To predict
which T1 N0 M0 lung adenocarcinomas are curable with
limited resection from CT findings, several reports have
evaluated the importance of ground-glass opacity (GGO)
within tumors, usually indicating bronchioloalveolar carci-
noma–like spread because adenocarcinomas with GGO ap-
pearance are more frequently N0 stage and have less tumor
involvement of intratumoral vessels or pleura than those
with a solid appearance.12,13 The criteria of defining GGO
appearance on CT scans are subjective, however, potentially
leading to erroneous selection of limited surgical interven-
tion.
In recent years, fluorodeoxyglucose (FDG) positron
emission tomography (PET) has been used to evaluate pul-
monary nodules and tumor stages. It has been reported that
FDG uptake correlates with the proliferative activity of
tumors14,15 and is an independent prognostic factor,16,17
particularly in lung adenocarcinoma. The prognosis in lung
adenocarcinoma is known to depend on not only tumor
stage but also tumor involvement of intratumoral vessels or
pleura.9,10,18 To predict lymph node metastases and tumor
involvement of intratumoral vessels or pleura in clinical T1
N0 M0 lung adenocarcinomas, we measured FDG uptake to
determine any correlation with lymph node metastases,
lymphatic and vascular invasion, and pleural involvement.
Materials and Methods
Patients
From December 2001 through October 2003, prospective FDG-
PET and CT scans were performed for 223 noncalcified pulmonary
nodules. Of these, 93 nodules were malignant tumors less than 3
cm in diameter on CT. Clinical TNM stage was determined by
using both CT and PET scanning. Of the 93 malignant nodules, 48
were clinical T1 N0 M0 adenocarcinomas of the lung, and these
underwent major lung resection with mediastinal lymph node
dissection. We excluded 4 adenocarcinomas less than 1 cm in
diameter that were PET negative because the spatial resolution of
the current generation of PET scanners is 0.7 to 0.8 cm, making it
difficult to image pulmonary nodules of less than 1 cm. As a result,
we studied 44 adenocarcinomas that were clinically staged as T1
N0 M0 of sizes from 1 to 3 cm. The medical record of each patient
The Journal of Thoraciwas examined with regard to age, sex, maximum tumor diameter,
serum level of carcinoembryonic antigen (CEA; 5 ng/mL vs 5
ng/mL), operative procedure, pathologic TNM stage, vascular or
lymphatic invasion within tumors (positive vs negative), pleural
involvement (p0 vs p1 to p3), and grade of histologic differentia-
tion. To identify tumor involvement of the intratumoral vessels or
pleura, we routinely conducted elastica-van Gieson staining. Pleu-
ral involvement was classified as p0, p1, p2, or p3; that is, a p0
tumor did not extend beyond the elastic pleural layer, a p1 tumor
invaded the visceral pleural elastic layer but did not reach the
pleural surface, a p2 tumor included tumor exposure on the pleural
surface, and a p3 tumor invaded the parietal pleura or chest wall.
The tumor stages were based on the TNM classification of the
International Union Against Cancer19: p2 tumors were classified as
T2; p3 tumors were classified as T3; and tumors with intrapulmo-
nary metastasis within the same lobe were classified as T4. Grades
of histologic differentiation were classified as well, moderately, or
poorly differentiated.
FDG-PET Scanning
Patients were instructed to fast for at least 4 hours before intrave-
nous administration of fluorine 18–tagged FDG. The dosage of
fluorine 18–tagged FDG administered was 125 Ci/kg (4.6 MBq/
kg) of body weight for nondiabetic patients and 150 Ci/kg (5.6
MBq/kg) of body weight for diabetic patients. PET imaging was
performed approximately 60 minutes after administration of FDG
with a POSICAM.HZL mPOWER (Positron Co, Houston, Tex).
No-attenuation-corrected emission scans were initially obtained in
2-dimensional, high-sensitivity mode for 4 minutes per bed posi-
tion and taken from the vertical skull through to the midthighs.
Immediately thereafter, a 2-bed-position attenuation-corrected ex-
amination was performed, with 6 minutes for the emission se-
quence and 6 minutes for the transmission sequence at each bed
position. The images were usually reconstructed in a 256  256
matrix by using ordered subset expectation maximization corre-
sponding to a pixel size of 4  4 mm, with section spacing of 2.66
mm.
PET Data Analysis
The FDG-PET data were evaluated semiquantitatively on the basis
of the contrast ratio (CR) obtained as follows. The regions of
interest (ROIs) were placed in the nodules and contralateral lung.
Highest activities in the tumor ROI (T) and in the contralateral
normal lung ROI (N) were measured. The CR was calculated by
using the formula (T  N)/(T  N) in each nodule as an index of
FDG uptake. After correction for radioactive decay, the ROIs were
also analyzed by computing the standard uptake value (SUV),
which was calculated on the basis of the following equation:
Tumor activity concentration/Injected dose/Body weight. The
maximum SUV within the selected ROIs was also measured and
compared with the results of CR.
Statistical Analysis
All data were analyzed for significance by using the 2-tailed
Student t test. All values in the text and tables are given as means
 SD.
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The pathologic tumor stage was T1 N0 M0 in 36 patients
and more advanced in 8 patients (ie, T1 N1 M0 in 3 patients,
T2 N0 M0 in 3 patients, and T4 N0 M0 in 2 patients).
Lymphatic or vascular invasion within tumors and pleural
involvement was seen in 19, 10, and 8 patients, respectively.
Table 1 shows the various CR values with relation to the
pathologic tumor stage, lymphatic and vascular invasion,
and pleural involvement. Although all adenocarcinomas
with a CR of less than 0.5 were pathologically staged as T1
N0 M0, some adenocarcinomas with a CR of 0.5 or greater
were more advanced than T1 N0 M0, with more frequent
lymphatic and vascular invasion and pleural involvement
than the former. Therefore medical records were compared
between the 22 adenocarcinomas with a CR of less than 0.5
and the 22 adenocarcinomas with a CR of 0.5 or greater.
The maximum SUVs ranged from 0.5 to 3.1 (mean, 1.1
 0.7) in the 22 adenocarcinomas with a CR of less than 0.5
and from 1.9 to 8.5 (mean, 3.9  1.8) in the 22 adenocar-
cinomas with CRs of 0.5 or greater, with the difference
between the 2 groups being significant (P  .001). Two
(9%) of the 22 adenocarcinomas with CRs of less than 0.5
TABLE 1. Tumor involvements and pathologic TNM stage
for each CR value
CR of FDG
uptake
Total
lesions >T1 N0 M0*
Lymphatic
invasion
Vascular
invasion
Pleural
involvement
0.3 16 0 5 1 1
0.4 19 0 5 1 1
0.5† 22 0 5 1 1
0.6 29 2 9 2 2
0.7 37 4 14 7 6
0.8 39 4 15 8 6
0.9 43 8 19 10 8
1.0 44 8 19 10 8
*Pathologically more advanced stages than T1 N0 M0. Three of the 8 cases
were p2; the other 5 were p1.
†Cutoff value of CR.
TABLE 2. PET findings and patients’ characteristics, tumor
size, and serum level of CEA
CR of FDG uptake P
value<0.5 (n  22) >0.5 (n  22)
Age (y, mean  SD) 63 11 64 13 NS
Male (No.) 14 10 NS
Female (No.) 8 12
Tumor size (cm, mean  SD) 1.9 0.6 2.2 0.4 NS
CEA (ng/mL) .001
5.0 22 10
5.0 0 12
NS, Not statistically significant.showed an SUV of 2.5 or greater, however, both of which
398 The Journal of Thoracic and Cardiovascular Surgery ● Septwere pathologically staged as T1 N0 M0 and had no in-
volvements of intratumoral vessels or pleura. Seven (32%)
of the 22 adenocarcinomas with CRs of 0.5 or greater had
SUVs of less than 2.5, of which 2 had a more advanced
tumor stage than T1 N0 M0, 6 had lymphatic invasion, and
1 had vascular invasion.
Table 2 shows the results of PET findings with patients’
characteristics, tumor size, and serum level of CEA. None
of the adenocarcinomas with CRs of less than 0.5 had
increased serum levels of CEA, which was significantly less
frequent than the incidence of increased CEA in the 12
(55%) of 22 adenocarcinomas with CRs of 0.5 or greater (P
 .001). There was no significant difference between the 2
groups in mean age, sex ratio, or tumor size.
Table 3 shows the correlation between PET findings and
pathologic tumor stage. All adenocarcinomas (100%) with
CRs of less than 0.5 were staged as T1 N0 M0. Adenocar-
cinomas with CRs of 0.5 or greater were staged as T1 N0
M0 in 14 (64%) patients, T1 N1 M0 in 3 patients, T2 N0 M0
caused by p2 (tumor exposure on the pleural surface) in 3
patients, and T4 N0 M0 caused by intrapulmonary metas-
tases in 2 patients. Adenocarcinomas with CRs of less than
0.5 were more likely to be pathologic T1 N0 M0 stage than
those with CRs of 0.5 or greater (P  .002).
Table 4 shows the correlation between PET findings and
lymphatic and vascular invasion within tumors and pleural
involvement. Lymphatic invasion was seen in 5 (23%) of 22
adenocarcinomas with CRs of less than 0.5, which was
significantly less frequent than 14 (64%) of 22 with CRs of
0.5 or greater (P  .006). Vascular invasion was seen in 1
(5%) of 22 adenocarcinomas with CRs of less than 0.5,
which was significantly less frequent than 9 (41%) of 22
with CRs of 0.5 or greater (P  .004). Pleural involvement
was seen in 1 (5%) of 22 adenocarcinomas with CRs of less
than 0.5, which was significantly less frequent than 7 (32%)
of 22 with CRs of 0.5 or greater (P  .02).
Table 5 shows the correlation between PET findings and
the histologic degree of differentiation. In the adenocarci-
TABLE 3. Correlation between PET findings and pathologic
tumor stage
Pathologic TNM Total (n  44)
CR of FDG uptake
<0.5 (n  22) >0.5 (n  22)
T1 N0 M0 36 22* 14*
T1 N1 M0 3 0 3
T2 N0 M0 3 0 3
T4 N0 M0 2 0 2
T2 is classified from pleural involvement grade, p2. T4 is classified from
intrapulmonary metastasis.
*Significant difference in the frequency of T1 N0 M0 between the CR 0.5
and CR 0.5 groups (P  .002).nomas with CRs of less than 0.5, well-differentiated and
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and 3 patients, respectively. In the adenocarcinomas with
CRs of 0.5 or greater, well-differentiated, moderately dif-
ferentiated, and poorly differentiated adenocarcinomas were
seen in 4, 14, and 4 patients, respectively. Adenocarcinomas
with CRs of less than 0.5 were more commonly well dif-
ferentiated than those with CRs of 0.5 or greater (P .001).
Table 6 shows the PET findings in well-differentiated
adenocarcinomas with relation to the tumor stages and
tumor involvements. Of the 4 well-differentiated adenocar-
cinomas with CRs of 0.5 or greater, each one (25%) was a
pathologic T1 N1 M0 and T4 N0 M0 carcinoma, respec-
tively; 4 (100%) had lymphatic invasion; 2 (50%) had
vascular invasion; and 2 (50%) had pleural involvement.
The well-differentiated adenocarcinomas with CRs of 0.5 or
greater had advanced tumor stages, lymphatic and vascular
invasion, and pleural involvement more frequently than
those with CRs of less than 0.5 (P .01, P .001, P .02,
and P  .01, respectively).
Discussion
Although a criterion for diagnosing pulmonary malignancy
with FDG-PET has frequently used an SUV with a cutoff
value of 2.5,20 some authors used visual evaluation, such as
comparison of FDG uptake between nodules and mediasti-
nal uptake.21 The present study evaluated FDG uptake with
CR instead of SUV for the following reasons: (1)hypergly-
cemia in diabetic patients decreases both the blood clear-
ance of FDG and the accumulation of FDG in tumor tissue,
and (2) SUV could be different between fat and thin patients
because it is measured by using a body weight. Actually, the
mean SUV of malignant pulmonary nodules has been re-
ported to be various, ranging from 5.5 to 10.1.22-25 In breast
cancer, Wahl and coworkers26 have demonstrated that a CR
between tumor and contralateral normal breast is a reliable
indicator for diagnosing malignancy. We accordingly used
CR in the present study and determined that the cutoff value
to differentiate between aggressive and nonaggressive ade-
TABLE 4. Correlation between PET findings and tumor in-
volvement into intratumoral vessels or pleura
Tumor involvement
CR of FDG uptake
P value<0.5 (n  22) >0.5 (n  22)
Lymphatic invasion .006
Yes 5 14
No 17 8
Vascular invasion .004
Yes 1 9
No 21 13
Pleural involvement .02
p0 21 15
p1-p2 1 7nocarcinomas was 0.5, with which we could differentiate
The Journal of Thoracithe degree of tumor aggressiveness more accurately than
with SUV.
The important points of the present study are as follows.
Compared with adenocarcinomas with CRs of 0.5 or
greater, those with CRs of less than 0.5 (1) did not show an
increased serum level of CEA, (2) did not have lymph node
metastases, (3) had less tumor involvement of vessels or
pleura, and (4) were more frequently well-differentiated
adenocarcinomas. The serum level of CEA in lung adeno-
carcinomas has been reported to be higher in N1 or N2
disease than in N0 disease.27 FDG uptake in lung adeno-
carcinomas is known to often be negative in well-differen-
tiated adenocarcinomas.28 It has been also reported that
well-differentiated adenocarcinomas are more commonly
N0 stage and have less tumor involvement of vessels or
pleura than moderately or poorly differentiated le-
sions.9,12,13,18 Our results agree with those of these earlier
studies. There were, however, 4 well-differentiated adeno-
carcinomas with CRs of 0.5 or greater that had more tumor
aggressiveness than the 19 well-differentiated lesions with
TABLE 5. Correlation between PET findings and grade of
histologic differentiation of adenocarcinomas
Grade of differentiation
Total
(n  44)
CR of FDG uptake
<0.5
(n  22)
>0.5
(n  22)
Well differentiated 23 19* 4*
Moderately differentiated 17 3 14
Poorly differentiated 4 0 4
There was significant difference in frequency of well-differentiated ade-
nocarcinomas between the CR 0.5 and CR 0.5 groups (P  .001).
TABLE 6. Correlation between PET findings and tumor
stages, tumor involvement of intratumoral vessels, and
tumor involvement of pleura in well-differentiated adeno-
carcinomas
Tumor stage and
invasiveness
CR of FDG uptake
P value>0.5 (n  19) >0.5 (n  4)
TNM stage .01
T1 N0 M0 19 2
T1 N0 M0 0 2
Lymphatic invasion .001
Yes 3 4
No 16 0
Vascular invasion .02
Yes 1 2
No 18 2
Pleural involvement .01
p0 19 2
p1-p2 0 2CRs of less than 0.5. We therefore consider that an FDG
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tumor invasiveness more accurately than the grade of his-
tologic differentiation in clinical T1 N0 M0 adenocarcino-
mas.
Although limited resection could be a reasonable ap-
proach for T1 N0 M0 lung cancers, it has been reported that
lymph node metastases are found in about 20% of clinical
T1 N0 M0 adenocarcinomas.9-11 In 1995, the Lung Cancer
Study Group reported the results of a randomized control
trial comparing limited resection and lobectomy for clinical
T1 N0 M0 NSCLCs.29 This trial demonstrated the inferior-
ity of limited resection in terms of local relapse and prog-
nosis because some patients actually had pathologic N1 or
N2 disease. This is also because tumor involvement of
intratumoral vessels or the pleura can cause local recurrence
after limited resection, even for pathologic N0 disease,
because of the spread of tumor cells into lymphatic vessels
outside the primary tumor.30 The present study showed that
clinical T1 N0 M0 adenocarcinomas with CRs of less than
0.5 usually did not metastasize to the lymph nodes and
seldom invaded the intratumoral vessels or pleura. This type
of lung adenocarcinoma can be cured by means of limited
surgical resection, such as segmentectomy or wedge resec-
tion. Although it has been reported that NSCLCs of less
than 2 cm in size can be cured by means of segmentectomy
with mediastinal lymph node dissection (ie, extended seg-
mentectomy),7 the indication of the extended segmentec-
tomy could be expanded for adenocarcinomas with CRs of
less than 0.5 that are less than 3 cm in size.
Mediastinal lymph node dissection is a useful procedure
to secure complete local control of an NSCLC, with a
subsequent improvement in both survival and nodal stag-
ing.11 However, to minimize the damage caused by medi-
astinal node dissection in the patients with clinical stage I
NSCLC, several authors reduced the dissection of some
mediastinal lymph nodal stations with respect to the loca-
tion of the primary tumor (ie, that the inferior and superior
mediastinal lymph node stations could be reduced in the
upper lobectomy and lower lobectomy, respectively).31,32
To expand the possibility of reduction of mediastinal lymph
node dissection, a successful intraoperative sentinel lymph
node biopsy has been reported.33,34 The present study
showed that lymph node dissection could be reduced for
clinical T1 N0 M0 adenocarcinomas with CRs of less than
0.5, without using the sentinel lymph node biopsy.
Although FDG-PET is well known to be useful for tumor
staging in lung cancer, we believe that it can also predict
lymph node metastases and tumor invasiveness in clinical
T1 N0 M0 lung adenocarcinomas. Limited lung resection
could be indicated, lymph node dissection or mediastinos-
copy could be reduced, or both in this type of adenocarci-
noma.
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